A071401 Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in

Recruiting

99 years and younger

All

Phase N/A

1 Location

Brief description of study

To determine the activity of a SMO inhibitor in patients with meningiomas harboring SMO and PTCH1 mutations as measured by 6-month PFS and response rate.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 04 Sep 2024. Study ID: 855383

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A071401 Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations

Brief description of study

Eligibility of study

Find a site

What happens next?

Interested in the study